Barclays’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $364M | Buy |
733,274
+70,011
| +11% | +$31M | 0.07% | 189 |
|
|
2026
Q1 | $296M | Sell |
663,263
-184,495
| -22% | -$86M | 0.07% | 204 |
|
|
2025
Q4 | $384M | Buy |
847,758
+105,271
| +14% | +$45.4M | 0.09% | 165 |
|
|
2025
Q3 | $291M | Sell |
742,487
-80,450
| -10% | -$33.6M | 0.06% | 222 |
|
|
2025
Q2 | $366M | Sell |
822,937
-2,993
| -0.4% | -$1.38M | 0.08% | 159 |
|
|
2025
Q1 | $400M | Sell |
825,930
-17,145
| -2% | -$7.99M | 0.11% | 136 |
|
|
2024
Q4 | $340M | Sell |
843,075
-96,261
| -10% | -$44.6M | 0.1% | 142 |
|
|
2024
Q3 | $437M | Buy |
939,336
+93,674
| +11% | +$45M | 0.12% | 129 |
|
|
2024
Q2 | $396M | Buy |
845,662
+28,247
| +3% | +$12.3M | 0.12% | 126 |
|
|
2024
Q1 | $342M | Buy |
817,415
+10,656
| +1% | +$4.5M | 0.12% | 141 |
|
|
2023
Q4 | $328M | Buy |
806,759
+550
| +0.1% | +$203K | 0.12% | 139 |
|
|
2023
Q3 | $280M | Buy |
806,209
+170,224
| +27% | +$59.5M | 0.17% | 125 |
|
|
2023
Q2 | $224M | Buy |
635,985
+199,923
| +46% | +$67.4M | 0.14% | 140 |
|
|
2023
Q1 | $137M | Sell |
436,062
-175,725
| -29% | -$52.7M | 0.06% | 203 |
|
|
2022
Q4 | $177M | Buy |
611,787
+198,887
| +48% | +$60.6M | 0.08% | 177 |
|
|
2022
Q3 | $120M | Buy |
412,900
+31,812
| +8% | +$9.15M | 0.13% | 153 |
|
|
2022
Q2 | $107M | Sell |
381,088
-190,947
| -33% | -$51.1M | 0.07% | 211 |
|
|
2022
Q1 | $149M | Sell |
572,035
-8,563
| -1% | -$2.03M | 0.12% | 173 |
|
|
2021
Q4 | $128M | Buy |
580,598
+11,895
| +2% | +$2.31M | 0.05% | 292 |
|
|
2021
Q3 | $103M | Buy |
568,703
+147,497
| +35% | +$28.8M | 0.05% | 310 |
|
|
2021
Q2 | $84.9M | Buy |
421,206
+44,907
| +12% | +$9.39M | 0.04% | 341 |
|
|
2021
Q1 | $80.9M | Sell |
376,299
-69,698
| -16% | -$15.3M | 0.04% | 318 |
|
|
2020
Q4 | $105M | Buy |
445,997
+59,702
| +15% | +$13.7M | 0.06% | 258 |
|
|
2020
Q3 | $105M | Buy |
386,295
+53,203
| +16% | +$14.7M | 0.06% | 229 |
|
|
2020
Q2 | $96.7M | Sell |
333,092
-349,050
| -51% | -$94.6M | 0.07% | 196 |
|
|
2020
Q1 | $162M | Sell |
682,142
-83,769
| -11% | -$19.2M | 0.13% | 113 |
|
|
2019
Q4 | $168M | Buy |
765,911
+342,430
| +81% | +$69.3M | 0.09% | 176 |
|
|
2019
Q3 | $71.7M | Buy |
423,481
+65,385
| +18% | +$11.6M | 0.04% | 337 |
|
|
2019
Q2 | $65.7M | Buy |
358,096
+90,157
| +34% | +$15.8M | 0.04% | 395 |
|
|
2019
Q1 | $49.3M | Sell |
267,939
-77,090
| -22% | -$14.2M | 0.03% | 449 |
|
|
2018
Q4 | $57.2M | Sell |
345,029
-110,037
| -24% | -$19.1M | 0.04% | 336 |
|
|
2018
Q3 | $87.7M | Buy |
455,066
+151,996
| +50% | +$27.1M | 0.06% | 240 |
|
|
2018
Q2 | $51.5M | Sell |
303,070
-162,581
| -35% | -$25.2M | 0.04% | 352 |
|
|
2018
Q1 | $75.9M | Buy |
465,651
+63,770
| +16% | +$10.4M | 0.06% | 273 |
|
|
2017
Q4 | $60.2M | Buy |
401,881
+134,325
| +50% | +$19.9M | 0.05% | 328 |
|
|
2017
Q3 | $40.7M | Buy |
267,556
+77,465
| +41% | +$11.7M | 0.04% | 379 |
|
|
2017
Q2 | $24.5M | Buy |
190,091
+9,662
| +5% | +$1.16M | 0.03% | 505 |
|
|
2017
Q1 | $19.7M | Buy |
180,429
+68,354
| +61% | +$6.02M | 0.02% | 564 |
|
|
2016
Q4 | $8.26M | Buy |
112,075
+21,249
| +23% | +$1.73M | 0.01% | 1050 |
|
|
2016
Q3 | $7.92M | Sell |
90,826
-8,746
| -9% | -$827K | 0.01% | 1004 |
|
|
2016
Q2 | $8.57M | Buy |
99,572
+1,684
| +2% | +$146K | 0.01% | 926 |
|
|
2016
Q1 | $7.73M | Sell |
97,888
-26,294
| -21% | -$2.38M | 0.01% | 907 |
|
|
2015
Q4 | $15.5M | Sell |
124,182
-4,737
| -4% | -$572K | 0.02% | 680 |
|
|
2015
Q3 | $13.4M | Sell |
128,919
-51,112
| -28% | -$6.57M | 0.02% | 786 |
|
|
2015
Q2 | $22.1M | Sell |
180,031
-22,017
| -11% | -$2.77M | 0.02% | 602 |
|
|
2015
Q1 | $23.6M | Buy |
202,048
+2,414
| +1% | +$289K | 0.03% | 599 |
|
|
2014
Q4 | $23.6M | Buy |
199,634
+16,501
| +9% | +$1.86M | 0.02% | 675 |
|
|
2014
Q3 | $20.5M | Sell |
183,133
-240,278
| -57% | -$22.9M | 0.02% | 702 |
|
|
2014
Q2 | $39.8M | Buy |
423,411
+165,349
| +64% | +$11.6M | 0.04% | 392 |
|
|
2014
Q1 | $18.1M | Sell |
258,062
-336,060
| -57% | -$26.6M | 0.02% | 756 |
|
|
2013
Q4 | $44M | Sell |
594,122
-154,489
| -21% | -$10.8M | 0.05% | 388 |
|
|
2013
Q3 | $56.1M | Buy |
748,611
+122,813
| +20% | +$9.77M | 0.07% | 258 |
|
|
2013
Q2 | $50.1M | Buy |
+625,798
| New | +$46.1M | 0.06% | 259 |
|
Other funds holding VRTX
Barclays's VRTX Position: Q2 2026 in Review
Barclays increased its Vertex Pharmaceuticals (VRTX) stake by 11% in Q2 2026, buying an estimated $31M and bringing the position to 733,274 shares worth $364M. The position accounts for 0.07% of the portfolio, ranked #189.
Barclays first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $437M in Q3 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Barclays held 733,274 shares of Vertex Pharmaceuticals worth $364M as of Q2 2026.
- Barclays bought 70,011 Vertex Pharmaceuticals shares in Q2 2026, an estimated $31M.
- Vertex Pharmaceuticals made up 0.07% of Barclays's portfolio in Q2 2026, its #189 holding.
- Barclays first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Barclays's Vertex Pharmaceuticals position peaked at $437M in Q3 2024.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.